Windlas Biotech Q1 FY27 Results: Revenue Rs 248 Cr, PAT Rs 17 Cr and Key Highlights
- August 11, 2026
- Posted by: Neeraj Pandey
- Category: News
Windlas Biotech Q1 FY27 results declared August 10, 2026. Revenue Rs 248 Cr (+18.09% YoY). PAT Rs 17 Cr (-0.07% YoY). CMP Rs 839.65 (-4.89%).
Windlas Biotech Q1 FY27 results were declared on August 10, 2026 on a standalone basis. Revenue expanded +18.09% YoY to Rs 248 Cr from Rs 210 Cr in Q1 FY26. The broader Nifty Pharma index reflected mixed sentiment during the quarter.
Operating profit stood at Rs 19 Cr (+2.08% YoY). PAT came in at Rs 17 Cr (-0.07% YoY), reflecting the key financial metrics of Windlas Biotech Q1 FY27 results.
Click Here – Get Free Investment Predictions
Windlas Biotech Q1 FY27 Financial Highlights
| Metric | Q1 FY27 (Rs Cr) | Q1 FY26 (Rs Cr) | YoY Change |
|---|---|---|---|
| Windlas Biotech Revenue | 248 | 210 | +18.09% |
| Operating Profit | 19 | 19 | +2.08% |
| Net Profit (PAT) | 17 | 17 | -0.07% |
| Reporting Basis | Standalone | ||
Windlas Biotech Q1 FY27 Performance Analysis
Check the Univest Screener for Live Data on This Stock
Windlas Biotech Q1 FY27 results reflect modest fundamentals. Revenue momentum were evident with the top line reaching Rs 248 Cr for the April to June 2026 quarter.
Operating profit expanded +2.08% YoY. PAT of Rs 17 Cr reflects -0.07% YoY movement. Investors tracking Windlas Biotech Q1 FY27 results will note these as key FY27 milestones.
Key Business Factors in Windlas Biotech Q1 FY27 Results
Revenue Expansion in Q1 FY27
Windlas Biotech Q1 FY27 results show revenue expanding +18.09% YoY to Rs 248 Cr from Rs 210 Cr in Q1 FY26. Volume-led growth and market share gains in the Pharmaceuticals segment drove the uptick.
Operating Margin Performance
Operating profit in Windlas Biotech Q1 FY27 results stood at Rs 19 Cr (+2.08% YoY). Better cost absorption and product mix improvement contributed to the operating performance.
PAT Trajectory and Profitability
PAT in Windlas Biotech Q1 FY27 results was Rs 17 Cr (-0.07% YoY), reflecting near-term operational challenges.
Dividend Details
No dividend was declared alongside Windlas Biotech Q1 FY27 results. Earnings are being channelled toward operational reinvestment and working capital.
FY27 Outlook for Windlas Biotech
Following Windlas Biotech Q1 FY27 results, management has focused on a recovery-driven strategy centred on cost reduction, revenue diversification, and return to profitability in the pharmaceuticals segment. Investors tracking Windlas Biotech Q1 FY27 results should consult a SEBI-registered financial advisor.
Windlas Biotech Stock Performance After Q1 FY27 Results
Download the Univest iOS App or Univest Android App to track Windlas Biotech live price and get daily stock recommendations.
Windlas Biotech shares were trading lower at Rs 839.65 (-4.89%) on August 10, 2026, reflecting investor sentiment on Windlas Biotech Q1 FY27 results and the near-term sector outlook. The CMP of Rs 839.65 on the results date reflects broader sentiment toward the pharmaceuticals space.
Key Risks for Windlas Biotech
Sector-Specific Risks
USFDA regulatory actions, generic pricing pressure, and API cost inflation remain core risks.
Valuation and Earnings Risk
Sustained margin compression and limited near-term earnings visibility may delay re-rating.
Operational and Financial Risk
Working capital intensity and cash conversion cycle elongation could strain standalone cash flows.
Conclusion
Windlas Biotech Q1 FY27 results reflect modest performance with revenue at Rs 248 Cr and PAT at Rs 17 Cr on a Standalone basis. Sector tailwinds and operational discipline will shape the FY27 trajectory. Investors should review management commentary before taking any position.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Windlas Biotech Q1 FY27 Results
When were Windlas Biotech Q1 FY27 results declared?
Ans. Windlas Biotech Q1 FY27 results were declared on August 10, 2026, covering the April–June 2026 quarter on a Standalone basis.
What was Windlas Biotech revenue in Q1 FY27?
Ans. Revenue in Windlas Biotech Q1 FY27 results was Rs 248 Cr, +18.09% YoY from Rs 210 Cr in Q1 FY26.
What was Windlas Biotech PAT in Q1 FY27?
Ans. Net profit in Windlas Biotech Q1 FY27 results was Rs 17 Cr (-0.07% YoY).
Did Windlas Biotech declare a dividend in Q1 FY27?
Ans. No dividend was announced alongside Windlas Biotech Q1 FY27 results. Refer to official NSE and BSE announcements for future dividend updates.
What is the FY27 outlook for Windlas Biotech?
Ans. Management has guided operational restructuring and return to profitability for FY27. Sector demand and execution will be key monitorables.
How did Windlas Biotech stock react to Q1 FY27 results?
Ans. Windlas Biotech shares were lower at Rs 839.65 (-4.89%) on August 10, 2026. Consult a SEBI-registered financial advisor before acting on price movements.
